Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vijay Benade

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Brain Research|April 3, 2012
Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition taskRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Biomolecules|February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain DisordersRamakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Neurology and Therapy|July 31, 2022
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled StudyRamakrishna Nirogi, Vinod Kumar Goyal, Vijay Benade, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2023
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjectsRamakrishna Nirogi, Jyothsna Ravula, Vijay Benade, et al.
Clinical Drug Investigation|August 13, 2022
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly SubjectsRamakrishna Nirogi, Vijay Benade, Vinod Kumar Goyal, et al.
Behavioural Pharmacology|May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRamakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Psychopharmacology|February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisationRamakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 6, 2022
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept studyRamakrishna Nirogi, John Ieni, Vinod Kumar Goyal, et al.
Journal of Psychopharmacology (Oxford, England)|February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disordersRamakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Brain Research|April 3, 2012
Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition taskRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Biomolecules|February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain DisordersRamakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Neurology and Therapy|July 31, 2022
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled StudyRamakrishna Nirogi, Vinod Kumar Goyal, Vijay Benade, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2023
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjectsRamakrishna Nirogi, Jyothsna Ravula, Vijay Benade, et al.
Clinical Drug Investigation|August 13, 2022
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly SubjectsRamakrishna Nirogi, Vijay Benade, Vinod Kumar Goyal, et al.
Behavioural Pharmacology|May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRamakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Psychopharmacology|February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisationRamakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 6, 2022
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept studyRamakrishna Nirogi, John Ieni, Vinod Kumar Goyal, et al.
Journal of Psychopharmacology (Oxford, England)|February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disordersRamakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Pageof 3